Evidence map›Paper›PMID 31937644›Full record

ArticlemBio2020

CpG Frequency in the 5' Third of the

Dorota Kmiec, Rayhane Nchioua, Scott Sherrill-Mix, Christina M Stürzel, Elena Heusinger, Elisabeth Braun, Marcos V P Gondim, Dominik Hotter, Konstantin M J Sparrer, Beatrice H Hahn and 2 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 63 citations in OpenAlex.

  1. Effects of Korean red ginseng on the HIV-1Journal of ginseng research · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Host ZAP activity correlates with the levels of CpG suppression in primate lentiviruses.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. A Bird's-Eye View of the Pathophysiologic Role of the Human Urobiota in Health and Disease: Can We Modulate It?Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Monkeypox: A New Threat?International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Dorota Kmiec *Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Rayhane Nchioua *Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Scott Sherrill-MixDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Christina M StürzelInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Elena HeusingerInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Elisabeth BraunInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Marcos V P GondimDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dominik HotterInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Konstantin M J SparrerInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Beatrice H HahnDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Daniel SauterInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany frank.kirchhoff@uni-ulm.de.
Universität Ulm · DEUniversity of Pennsylvania · US

Funding

Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9M
Natural SIV Reservoirs and Human Zoonotic RiskR01AI050529 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2001 to 2022
$6.1M
Great Ape Reservoirs of Human MalariaR01AI091595 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2011 to 2019
$5.3M
Restriction of HIV-1 transmission by type 1 interferonsR01AI114266 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2014 to 2018
$3.2M
NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI050529NIAID NIH HHS R01 AI091595NIAID NIH HHS R01 AI114266NIAID NIH HHS R37 AI150590NIAID NIH HHS UM1 AI126620
6 · The paper itself

Abstract

CpG dinucleotide suppression has been reported to allow HIV-1 to evade inhibition by the zinc-finger antiviral protein (ZAP). Here, we show that primate lentiviruses display marked differences in CpG frequencies across their genome, ranging from 0.44% in simian immunodeficiency virus SIVwrc from Western red colobus to 2.3% in SIVmon infecting mona monkeys. Moreover, functional analyses of a large panel of human and simian immunodeficiency viruses revealed that the magnitude of CpG suppression does not correlate with their susceptibility to ZAP. However, we found that the number of CpG dinucleotides within a region of ∼700 bases at the 5' end of the

Indexed as

CpG Islandsenv Gene Products, Human Immunodeficiency VirusGenome, ViralHEK293 CellsHIV-1HIV-2HumansRNA-Binding ProteinsSimian Immunodeficiency VirusVirus Replicationenv Gene Products, Human Immunodeficiency VirusRNA-Binding ProteinsZC3HAV1 protein, humanCpG dinucleotidesenvelope genehuman immunodeficiency virusrestriction factorszinc-finger antiviral protein

Identifiers

PMID31937644
PMCPMC6960287
OpenAlexW3000475974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.